When MMV enters into contractual relationships with partners, our primary goal is social responsibility. This means that we encourage our partners to work with us to ensure that the effective and high quality malaria drugs that we develop and launch will be accessible to those most in need in malaria-endemic countries.

We ensure first and foremost that our agreements meet our public health mission. While we understand academia and the private industry’s need to protect their intellectual property rights, we endeavour to negotiate for our new medicines to be made available at an affordable price – typically with no profit and no loss – through public sector channels. 

→Read our intellectual property policy.

→Read an article on our approach to intellectual property.